O'Connell Daniel, Seikaly Hadi, Murphy Russell, Fung Charles, Cooper Tim, Knox Aaron, Scrimger Rufus, Harris Jeffrey R
Division of Otolaryngology-Head & Neck Surgery, University of Alberta, Edmonton, AB, Canada.
Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
J Otolaryngol Head Neck Surg. 2013 Apr 22;42(1):31. doi: 10.1186/1916-0216-42-31. eCollection 2013.
Treatment for advanced stage oropharyngeal squamous cell carcinoma (OPSCC) includes combined chemoradiation therapy or surgery followed by radiation therapy alone or in combination with chemotherapy. The goal of this study was to utilize available evidence to examine survival outcome differences in patients with advanced stage OPSCC treated with these different modalities.
Patients with advanced stage OPSCC were identified. Primary outcome measurements were disease specific and overall survival rates with differences examined via Kaplan-Meier and logistic regression analysis.
344 patients were enrolled. 94 patients underwent triple modality therapy inclusive of surgery followed by adjuvant combined chemotherapy and radiation therapy (S-CRT). 131 had surgery and radiation therapy (S-RT), while 56 had chemoradiation (CRT) therapy as their primary treatment. A total of 63 patients had single modality radiation therapy and were excluded from analysis due to the large number of palliative patients. Kaplan-Meier overall survival analysis showed that therapy with S-CRT had the highest disease specific survival at five years (71.1%). This is contrasted against S-RT and CRT, with five year survival rates at 53.9%, and 48.6%, respectively. Cox regression showed that the comparison of S-CRT vs. S-RT, and CRT is associated with statistically significant increased hazard ratios of 1.974, and 2.785, indicating that both S-RT and CRT are associated with a reduced likelihood of survival at 5 years when compared to S-CRT.
In this population based cohort study S-CRT is associated with a 17-22% 5 year disease specific survival benefit compared to CRT or S-RT.
晚期口咽鳞状细胞癌(OPSCC)的治疗包括联合放化疗或手术,术后单独放疗或联合化疗。本研究的目的是利用现有证据,研究采用这些不同治疗方式的晚期OPSCC患者的生存结果差异。
确定晚期OPSCC患者。主要结局指标为疾病特异性生存率和总生存率,通过Kaplan-Meier法和逻辑回归分析检验差异。
共纳入344例患者。94例患者接受了三联疗法,包括手术,随后进行辅助联合化疗和放疗(S-CRT)。131例接受了手术和放疗(S-RT),而56例以放化疗(CRT)作为主要治疗方法。共有63例患者接受了单一放疗,由于大量姑息治疗患者,被排除在分析之外。Kaplan-Meier总生存分析显示,S-CRT治疗的患者5年疾病特异性生存率最高(71.1%)。相比之下,S-RT和CRT的5年生存率分别为53.9%和48.6%。Cox回归显示,S-CRT与S-RT和CRT相比,危险比分别显著增加1.974和2.785,这表明与S-CRT相比,S-RT和CRT在5年时的生存可能性均降低。
在这项基于人群的队列研究中,与CRT或S-RT相比,S-CRT在5年疾病特异性生存方面有17%-22%的获益。